Michael Wheatcroft
Chief Tech/Sci/R&D Officer en TELIX PHARMACEUTICALS LIMITED .
Perfil
Michael Wheatcroft is currently the Chief Scientist at Telix Pharmaceuticals Ltd.
He previously worked as a Principal at Medimmune UK Ltd.
and as a Research Manager at Avipep Pty Ltd.
He holds a doctorate degree from the University of Cambridge.
Cargos activos de Michael Wheatcroft
| Empresas | Cargo | Inicio |
|---|---|---|
| TELIX PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | - |
Antiguos cargos conocidos de Michael Wheatcroft.
| Empresas | Cargo | Fin |
|---|---|---|
Medimmune UK Ltd.
 Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Corporate Officer/Principal | - |
Avipep Pty Ltd.
 Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Corporate Officer/Principal | - |
Formación de Michael Wheatcroft.
| University of Cambridge | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| TELIX PHARMACEUTICALS LIMITED | Health Technology |
| Empresas privadas | 2 |
|---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Process Industries |
Avipep Pty Ltd.
Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Wheatcroft
